Stockscreener 앱 받기
118.92
8.36%
9.17
시간 외 거래:
117.25
-1.67
-1.40%
전일 마감가:
$109.75
열려 있는:
$123
하루 거래량:
5.01M
Relative Volume:
3.19
시가총액:
$10.61B
수익:
$2.24B
순이익/손실:
$385.90M
주가수익비율:
31.88
EPS:
3.73
순현금흐름:
$440.10M
1주 성능:
+10.89%
1개월 성능:
+24.33%
6개월 성능:
-5.09%
1년 성능:
-16.08%
1일 변동 폭
$116.56
$130.46
1주일 범위
$105.45
$130.46
52주 변동 폭
$84.23
$157.98
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
118.92 | 10.61B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
149.87 | 69.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.17 | 48.09B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.67 | 46.34B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.12 | 18.47B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
295.02 | 13.57B | 2.76B | 1.11B | 898.10M | 22.77 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May - Longview News-Journal
Neurocrine Biosciences (NBIX) Price Target Raised by RBC Capital | NBIX Stock News - GuruFocus
Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target - Benzinga
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com
Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target By Investing.com - Investing.com India
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug - inkl
RBC Capital lifts Neurocrine Bio. stock target to $145 on sales momentum - Investing.com
NBIX: Analyst BMO Capital Raises Price Target for Neurocrine Biosciences | NBIX Stock News - GuruFocus
Neurocrine Biosciences (NBIX) Target Price Raised by UBS Analyst | NBIX Stock News - GuruFocus
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong R - GuruFocus
BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating - marketscreener.com
Wedbush Boosts Neurocrine (NBIX) Price Target Following Strong Results | NBIX Stock News - GuruFocus
Guggenheim Ups Price Target for Neurocrine (NBIX) Amid Ingrezza Sales Performance | NBIX Stock News - GuruFocus
Neurocrine Bio stock target raised at Needham following earnings - Investing.com
RBC Capital Increases Price Target for Neurocrine (NBIX) to $145 | NBIX Stock News - GuruFocus
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Eastern Progress
UBS Elevates Neurocrine (NBIX) Price Target and Highlights Growth Prospects | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earni - GuruFocus
RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences (NBIX) Receives Price Target Raise from Canaccord Genuity | NBIX Stock News - GuruFocus
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga
Analyst Maintains Buy Rating on Neurocrine Biosciences (NBIX) with Raised Price Target | NBIX Stock News - GuruFocus
Neurocrine (NBIX) Sees Price Target Increased Following Strong Q1 Performance | NBIX Stock News - GuruFocus
S&P 500 Futures Drop in Premarket Trading; Neurocrine Biosciences, Regal Rexnord Lead - Barron's
Palantir, Ford, Tesla, Constellation Energy, Clorox, Hims & Hers, Neurocrine, AMD, and More Movers - Barron's
Neurocrine Biosciences (NBIX) Price Target Increased by Canaccor - GuruFocus
Neurocrine (NBIX) Sees Price Target Adjustment Amid Strong Earnings Report | NBIX Stock News - GuruFocus
Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More Market Movers - Barron's
Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... By GuruFocus - Investing.com Canada
Neurocrine Biosciences Reports Strong Q1 2025 Results - TipRanks
Neurocrine: Q1 Earnings Snapshot - The Washington Post
Neurocrine Biosciences (NBIX) Surges 13% After Strong Q1 Results - GuruFocus
Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - Seeking Alpha
Earnings call transcript: Neurocrine Biosciences Q1 2025 results miss EPS expectations - Investing.com
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates - Yahoo Finance
Neurocrine Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neurocrine Biosciences stock soars on strong INGREZZA guidance By Investing.com - Investing.com South Africa
Neurocrine Biosciences stock soars on strong INGREZZA guidance - Investing.com
NBIX Reports Strong Q1 Revenue and Reaffirms Sales Guidance | NBIX Stock News - GuruFocus
Earnings Flash (NBIX) Neurocrine Biosciences Posts Q1 Revenue $572.6M, vs. FactSet Est of $559.6M - marketscreener.com
Earnings Flash (NBIX) Neurocrine Biosciences Reports Q1 Adjusted EPS $0.70 - marketscreener.com
Neurocrine Biosciences Inc Q1 Profit Decreases, Misses Estimates - Nasdaq
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance - PR Newswire
Neurocrine Biosciences Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia - PR Newswire
Neurocrine Biosciences (NBIX) Prepares for Q1 Earnings Announcem - GuruFocus
Neurocrine Biosciences (NBIX) Prepares for Q1 Earnings Announcement - GuruFocus
BlackRock, Inc. Reduces Stake in Neurocrine Biosciences Inc - GuruFocus
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 - GlobeNewswire Inc.
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.28%
자본화:
|
볼륨(24시간):